All In Biotech

Drug Trial Radar · NCT06593457

A Food-Effect, Drug-Drug Interaction, and Pharmacokinetics Study of NX-5948 in Healthy Adult Subjects

A Phase 1, 2-Part, Placebo-Controlled, Double-Blinded Study to Assess the Effect of Food and Drug-Drug Interaction of Fluconazole on the Pharmacokinetics of NX-5948

Last checked: Nov 19, 2026Latest source record: Mar 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

32

Actual

Start

Aug 20, 2024

Primary completion

Oct 29, 2024

Study completion Nov 14, 2024

Sponsor

Lead sponsor
Nurix Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Sep 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a Phase 1, 2-part double-blinded (with respect to NX-5948/placebo), placebo-controlled study. Part 1 is a randomized, 3 period cross-over food-effect (FE) and drug-drug interaction (DDI) study. Part 2 is a single-period PK evaluation study.

Conditions

  • Healthy Volunteers

Interventions

  • IPDrug

    NX-5948 oral

  • Matching PlaceboDrug

    Fluconazole

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1 Food Effect: AUC0-t for NX-5948 administered under fed and fasted conditionsTime frame: 9 weeks
  2. Part 1 Food Effect: AUC0-inf for NX-5948 administered under fed and fasted conditionsTime frame: Approximately 9 weeks
  3. Part 1 Food Effect: Cmax for NX-5948 administered under fed and fasted conditionsTime frame: 9 weeks
  4. Part 1 Drug Drug Interaction: AUC0-inf for NX-5948 administered with and without fluconazoleTime frame: 9 weeks
  5. Part 1 Drug Drug Interaction: Cmax for NX-5948 administered with and without fluconazoleTime frame: 9 weeks
  6. Part 1 Drug Drug Interaction: AUC0-t for NX-5948 administered with and without fluconazoleTime frame: Approximately 9 weeks
  7. Part 2 PK: AUC0-inf for NX-5948 administrationTime frame: 6 weeks
  8. Part 2 PK: Cmax for NX-5948 administrationTime frame: 6 weeks
  9. Part 2 PK: AUC0-t for NX-5948 administrationTime frame: Approximately 6 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Celerion

    Lincoln, Nebraska

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.